CroFab® Is Proven to Control Envenomation in Pediatric and Adult Patients
Gaining Initial Control With CroFab®
In 2 open-label trials with 42 patients with mild or moderate envenomation1,2*:
- 98% of patients administered CroFab® gained initial control
- 95% of patients showed a clinical response† 1 hour after initial control
In a placebo-controlled trial of 74 patients with copperhead envenomation published in 2017‡, CroFab® administration resulted in improved limb function vs placebo on Day 14 post envenomation.3
Watch Dr. Rutherfoord Rose discuss using CroFab® to treat copperhead envenomation.
Continuing Control With CroFab®
Scheduled maintenance dosing after initial control lowered incidence of coagulation abnormalities due to residual venom.1
Fewer coagulation abnormalities with scheduled maintenance dosing1
No local progression with scheduled maintenance dosing4
Review the safety profile you can count on.
1. CroFab® [prescribing Information]. BTG International Inc; January 2018. 2. Data on file. Conshohocken, PA; BTG International Inc. 2019. 3. Gerardo CJ, Quackenbush E, Lewis B, et al. The efficacy of crotalidae polyvalent immune fab (ovine) antivenom versus placebo plus optional rescue therapy on recovery from copperhead snake envenomation: A randomized, double-blind, placebo-controlled clinical trial. Ann Emerg Med. 2017;70(2):233-244. 4. Dart RC, Seifert SA, Boyer LV, et al. A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med. 2001;161(16):2030-2036.